549P Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study.
Saved in:
| Title: | 549P Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study. |
|---|---|
| Authors: | André, T.1 (AUTHOR), Berton-Rigaud, D.2 (AUTHOR), Curigliano, G.3 (AUTHOR), Sabatier, R.4 (AUTHOR), Tinker, A.V.5 (AUTHOR), Oaknin, A.6 (AUTHOR), De Braud, F.G.M.7 (AUTHOR), Ellard, S.8 (AUTHOR), Arkenau, H-T.9 (AUTHOR), Trigo Perez, J.M.10 (AUTHOR), Brown, J.11 (AUTHOR), Jewell, A.12 (AUTHOR), Pikiel, J.13 (AUTHOR), Mirza, M.R.14 (AUTHOR), Duan, T.15 (AUTHOR), Antony, G.16 (AUTHOR), Zildjian, S.17 (AUTHOR), Zografos, E.18 (AUTHOR), Veneris, J.17 (AUTHOR), Banerjee, S.19 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS799-S800. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.677 |
